Vapotherm, Inc. (VAPO): Price and Financial Metrics
GET POWR RATINGS... FREE!
VAPO POWR Grades
- Sentiment is the dimension where VAPO ranks best; there it ranks ahead of 66.78% of US stocks.
- VAPO's strongest trending metric is Momentum; it's been moving down over the last 179 days.
- VAPO ranks lowest in Quality; there it ranks in the 7th percentile.
VAPO Stock Summary
- Vapotherm Inc's stock had its IPO on November 14, 2018, making it an older stock than merely 10.73% of US equities in our set.
- Revenue growth over the past 12 months for Vapotherm Inc comes in at -9.89%, a number that bests only 10.84% of the US stocks we're tracking.
- The volatility of Vapotherm Inc's share price is greater than that of 74.86% US stocks with at least 200 days of trading history.
- If you're looking for stocks that are quantitatively similar to Vapotherm Inc, a group of peers worth examining would be TRUE, AXGN, REKR, BIOC, and XGN.
- Visit VAPO's SEC page to see the company's official filings. To visit the company's web site, go to www.vapotherm.com.
VAPO Valuation Summary
- VAPO's price/earnings ratio is -12.5; this is 134.25% lower than that of the median Healthcare stock.
- Over the past 34 months, VAPO's EV/EBIT ratio has gone down 4.7.
- Over the past 34 months, VAPO's EV/EBIT ratio has gone down 4.7.
Below are key valuation metrics over time for VAPO.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| VAPO | 2021-08-31 | 5.8 | 7.7 | -12.5 | -12.6 |
| VAPO | 2021-08-30 | 5.9 | 7.8 | -12.7 | -12.8 |
| VAPO | 2021-08-27 | 5.7 | 7.6 | -12.4 | -12.5 |
| VAPO | 2021-08-26 | 5.7 | 7.7 | -12.5 | -12.5 |
| VAPO | 2021-08-25 | 5.4 | 7.3 | -11.8 | -11.9 |
| VAPO | 2021-08-24 | 5.5 | 7.3 | -11.9 | -12.0 |
VAPO's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- VAPO has a Quality Grade of F, ranking ahead of 3.49% of graded US stocks.
- VAPO's asset turnover comes in at 0.702 -- ranking 53rd of 186 Medical Equipment stocks.
- 500 - Internal server error
The table below shows VAPO's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-09-30 | 0.702 | 0.501 | -0.633 |
| 2021-06-30 | 0.636 | 0.505 | -0.633 |
| 2021-03-31 | 0.680 | 0.511 | -0.536 |
| 2020-12-31 | 0.688 | 0.501 | -0.623 |
| 2020-09-30 | 0.624 | 0.493 | -0.583 |
| 2020-06-30 | 0.572 | 0.480 | -0.610 |
VAPO Stock Price Chart Interactive Chart >
VAPO Price/Volume Stats
| Current price | $3.15 | 52-week high | $31.87 |
| Prev. close | $3.07 | 52-week low | $2.82 |
| Day low | $2.98 | Volume | 295,600 |
| Day high | $3.17 | Avg. volume | 289,445 |
| 50-day MA | $8.42 | Dividend yield | N/A |
| 200-day MA | $17.99 | Market Cap | 83.68M |
Vapotherm, Inc. (VAPO) Company Bio
Vapotherm Inc. Vapotherm, Inc. is a global medical technology company. The Company is focused on the development and commercialization of its high velocity nasal insufflations (Hi-VNI) technology products that are used to treat patients suffering from respiratory distress. Its Hi-VNI technology delivers noninvasive ventilatory support by providing heated, humidified and oxygenated air at a high velocity to patients through a comfortable small-bore nasal interface. Its Precision Flow systems uses its Hi-VNI technology. It offers three versions of its Precision Flow systems: Precision Flow Plus, Precision Flow Classic and Precision Flow Heliox. Its Precision Flow systems include a capital unit, a single-use disposable and a nasal interface. Its Precision Flow versions are integrated systems that provide precise user control of temperature, air flow and percentage oxygen through a one-button interface.
Latest VAPO News From Around the Web
Below are the latest news stories about Vapotherm Inc that investors may wish to consider to help them evaluate VAPO as an investment opportunity.
Vapotherm Reports Fourth Quarter and Fiscal Year 2021 Financial ResultsEXETER, N.H., February 24, 2022--Vapotherm, Inc. (NYSE: VAPO), ("Vapotherm" or the "Company"), a global medical technology company focused on the development and commercialization of its innovative, comfortable, non-invasive technologies for respiratory support of patients with chronic or acute breathing disorders today announced fourth quarter and fiscal year 2021 financial results. |
Vapotherm to Report Fourth Quarter and Full Year 2021 Financial ResultsEXETER, N.H., February 10, 2022--Vapotherm, Inc. (NYSE: VAPO) ("Vapotherm" or the "Company"), a global medical technology company focused on the development and commercialization of its innovative, comfortable, non-invasive technologies for respiratory support of patients with chronic or acute breathing disorders, today announced that it will release financial results for the fourth quarter and full year 2021 after the close of trading on Thursday, February 24, 2022. Vapotherm’s management team |
Vapotherm Stock: Speculative, but High-Upside IndustryI am neutral on Vapotherm (VAPO) as it operates in a high-upside, innovative industry and enjoys the support of Wall Street analysts with an average price target that implies massive upside over the next year. However, the company is very speculative as it is far from profitable and is currently facing declining revenue. Vapotherm develops medical technology products, specifically respiratory devices for treating breathing disorders. The company is focused on the commercialization of proprietary high velocity therapy products and currently offers flow systems, such as Precision Flow Classic, Precision Flow Heliox, and Precision Flow Plus. |
Is Vapotherm (NYSE:VAPO) Using Debt In A Risky Way?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says... |
BTIG Thinks Vapotherm’s Stock is Going to RecoverBTIG analyst Marie Thibault reiterated a Buy rating on Vapotherm (VAPO – Research Report) today and set a price target of $45.00. The company's shares closed last Tuesday at $19.49, close to its 52-week low of $16.64. According to TipRanks.com, Thibault is a 5-star analyst with an average return of 29.4% and a 43.7% success rate. Thibault covers the Healthcare sector, focusing on stocks such as Establishment Labs Holdings, Edwards Lifesciences, and Irhythm Technologies. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Vapotherm with a $41.00 average price target. |
VAPO Price Returns
| 1-mo | -42.41% |
| 3-mo | -76.70% |
| 6-mo | -85.24% |
| 1-year | -83.00% |
| 3-year | -80.73% |
| 5-year | N/A |
| YTD | -84.79% |
| 2021 | -22.90% |
| 2020 | 120.89% |
| 2019 | -39.05% |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...